Pfizer launches early safety trial for new kidney disease drug
NCT ID NCT06994897
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new medicine called PF-07985631, which may one day treat a kidney disease called IgA nephropathy. About 92 healthy adults will receive either the study drug or a placebo as an injection or IV. The main goal is to check safety and how the body processes the drug, not to treat any illness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Clinical Research Unit - Brussels
RECRUITINGBrussels, Bruxelles-capitale, Région de, B-1070, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test